

Clinical Practice Guidelines Overview: Pediatric Outpatient Antimicrobial Recommendations for Select Head and Chest Infections

Bronchiolitis and common cold (non-specific upper respiratory tract infection/URI) are not included due to viral etiology. Antibiotic therapy is not routinely recommended unless concern for bacterial superinfection as below.

Diagnosis	Indication for Testing or Treatment	First-line therapy:	Second-line or failure*	Non-type 1 β -lactam allergy	Severe type 1 β -lactam allergy	Duration
Acute Otitis Media (AOM) Children over 2 months old	1. Severe bilateral or unilateral AOM (moderate to severe otalgia, otalgia >48h, or temperature > 39°C) 2. Mild bilateral AOM for children <2 years of age 3. Considerations to watch and wait: <ol style="list-style-type: none"> Unilateral AOM for children 6 months to 23 months Bilateral or unilateral AOM in children >2 years of age If failure*, initiation of antibiotic therapy is warranted 4. Use second-line recommendation if failure*, in presence of purulent conjunctivitis, or receipt of amoxicillin within 30 days	Watchful waiting OR Amoxicillin 90 mg/kg/day divided BID (max: 1000 mg/dose) If tubes: Ofloxacin Otic 5 drops in affected ear BID or Ciprofloxacin/Dexamethasone Otic 4 drops BID for 10 days	Amoxicillin-clavulanate 90 mg/kg/day (amoxicillin component) divided BID (max: 1000 mg/dose) Ceftriaxone 50 mg/kg IM daily x3 days (max: 2000 mg/dose)	Cefdinir 14 mg/kg/day divided BID (max: 300mg/dose)	Levofloxacin Age <5 yrs: 20 mg/kg/day divided BID (max: 250 mg/dose) Age \geq 5 yrs: 10 mg/kg daily (max: 500 mg/dose)	<2 years of age: 10 days \geq 2 years of age: 7 days
Group A Streptococcus Pharyngitis (GAS)	1. Discriminate between GAS vs viral pharyngitis with use of rapid antigen detection test (RADT), PCR, or throat culture 2. Testing and treatment not routinely indicated: <ol style="list-style-type: none"> Presumed viral pharyngitis with associated rhinorrhea, cough, oral ulcers, hoarseness Children < 3 yrs of age, unless risk factors or close contact with GAS 3. For recurrent episodes of pharyngitis, consider possibility of chronic carrier status which does not routinely require treatment	Amoxicillin 50 mg/kg once daily (max: 1000 mg/dose) for 10 days OR Benzathine Penicillin G IM x1 dose \leq 27 kg 600,000 units >27 kg 1,200,000 units		Cephalexin 40 mg/kg/day divided BID (max: 500 mg/dose)^ for 10 days	Azithromycin 12 mg/kg once daily (max: 500 mg daily/dose) for 5 days	See specific medication therapy
Acute Infectious Conjunctivitis	1. Conjunctival infection, purulent discharge 2. Difficult to differentiate between viral vs. bacterial conjunctivitis 3. Extremely contagious, encourage good hand washing	Polymyxin B/Trimethoprim Ophthalmic drops 1-2 drops four times daily	Aminoglycoside or Fluoroquinolone Ophthalmic drops are acceptable alternatives, <u>however</u> <u>moxifloxacin should be reserved for ophthalmology use</u>			7 days

Diagnosis	Indication for Testing or Treatment	First-line therapy:	Second-line or failure*	Non-type 1 β-lactam allergy	Severe type 1 β-lactam allergy	Duration
Bacterial Sinusitis	<ol style="list-style-type: none"> Persistent nasal discharge or daytime cough lasting >10 days without improvement Worsening or new onset nasal discharge, daytime cough, headache or fever after initial improvement Severe onset (temperature ≥ 39°C, facial pain, purulent nasal discharge for ≥3 days) <ol style="list-style-type: none"> Typical age is 4-7 years, less common <2 yrs of age. Sinus development = maxillary/ethmoid (birth-age 4) > sphenoid (age 2-5) > frontal (age 7 – adulthood) 	<p>Watchful waiting</p> <p>OR</p> <p>Severe or Worsening Symptoms: Amoxicillin-clavulanate 90 mg/kg/day (amoxicillin component) divided BID (max: 2000 mg/dose)</p> <p>OR</p> <p>Persistent Symptoms Only: Amoxicillin 90 mg/kg/day divided BID (max: 2000 mg/dose)</p>	<p>Clindamycin 40 mg/kg/day divided TID (max: 600 mg/dose)</p> <p>PLUS EITHER Cefpodoxime 10 mg/kg/day divided BID (max: 200 mg/dose)</p> <p>OR</p> <p>Cefixime 8 mg/kg/day divided BID (max: 200 mg/dose)</p>	<p>Clindamycin 40 mg/kg/day divided TID (max: 600 mg/dose)</p> <p>PLUS EITHER Cefpodoxime 10 mg/kg/day divided BID (max: 200 mg/dose)</p> <p>OR</p> <p>Cefixime 8 mg/kg/day divided BID (max: 200 mg/dose)</p>	<p>Levofloxacin Age <5 yrs: 20 mg/kg/day divided BID (max: 250 mg/dose)</p> <p>Age ≥5 yrs: 10mg/kg daily (max: 500 mg/dose)</p>	Minimum 10 days, continue 7 days after resolution of symptoms
Community-Acquired Pneumonia (CAP)	<ol style="list-style-type: none"> Mild-moderate CAP suspected bacterial in origin Consider inpatient therapy if respiratory distress, hypoxemia, inadequate follow up, not tolerating oral therapy 	<p>Amoxicillin 90 mg/kg/day divided BID (max: 2000 mg/dose)</p> <p>≥ 5 yrs old consider adding coverage for atypical pneumonia Azithromycin 10 mg/kg day 1 (max 500 mg/dose) followed by 5 mg/kg days 2-5 (max 250 mg/dose)</p> <p>Influenza pneumonia: Oseltamivir- 5 days course <i>For children ≥12 months</i> ≤15 kg: 30 mg/dose twice daily >15 to 23 kg: 45 mg/dose twice daily >23 to 40 kg: 60 mg/dose twice daily >40 kg: 75 mg/dose twice daily</p> <p><i>For children < 12 months</i> 1-8 months: 3 mg/kg/dose twice daily 9-11 months: 3.5 mg/kg/dose twice daily</p>	<p>Amoxicillin-clavulanate 90 mg/kg/day divided BID (max: 2000 mg/dose)</p>	<p>First line: Clindamycin 40 mg/kg/day divided TID (max 600 mg/dose)</p> <p>Second line: Clindamycin PLUS EITHER Cefpodoxime 10 mg/kg/day divided BID (max :200 mg/dose)</p> <p>OR</p> <p>Cefixime 8 mg/kg/day divided BID (max: 200 mg/dose)</p>	<p>First line: Clindamycin 40 mg/kg/day divided TID (max 600 mg/dose)</p> <p>Second line: Levofloxacin Age 6 months – 5 yrs: 20 mg/kg/day divided BID (max: 375 mg/dose)</p> <p>Age ≥5 yrs: 10 mg/kg/day (max 750 mg/dose)</p>	10 days

- Bradley JS, et al. *The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America*. Clin Infect Dis 2011. e1-e52.
- Chow AW, et al. *IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults*. Clin Infect Dis 2012. 54(8): e72-112.
- Cronau H, et al. *Diagnosis and Management of Red Eye in Primary Care*. Am Fam Physician 2010. 81:137-44. L. Moore, A. Desai, E. Johnson, B. Kilbane, D. Hertz July 2017
- Lieberthal AS, et al. *The Diagnosis and Management of Acute Otitis Media*. Pediatrics 2013. 131(3): e964-99.
- Shulman ST, et al. *Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America*. Clin Infect Dis 2012. 55(10):1279-82.
- Wald ER, et al. *Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 years*. Pediatrics 2013. 132(1): e262-80.

*Failure is defined as lack of clinical improvement within 48-72 hours

^Do not use if anaphylaxis, angioedema, urticaria, or bronchospasm to β -lactam; consider ID consultation for treatment recommendations or Allergy referral for penicillin allergy testing.

~This handout is intended to provide a framework for clinical decision-making and is not meant to replace clinical judgment

© 2020 University Hospitals Health System, Inc.

The contents of University Hospitals Quality Care Network (“QCN”) clinical practice guidelines (“CPGs”) are to be used as practical and deliberately brief guides for licensed QCN provider participants. CPGs are not strict protocols and do not replace a licensed QCN provider participant’s clinical judgment nor are they meant to be a replacement for licensed QCN provider participant’s training, experience, continuing medical education and self-study on the latest literature and drug information. QCN has made every effort to ensure that the information provided in CPGs are based upon best available scientific evidence at the time of publication. Nonetheless, the CPGs should never be relied on as a substitute for proper assessment with respect to the particular circumstances of each case and the needs of each patient. QCN accepts no responsibility for any inaccuracies in a CPG, evidence based changes to best practices after publication of a CPG, or outcomes of any treatment regime recommended within a CPG. Send feedback to: Brad Hillard, DO UH Quality Care Network Medical Director (Bradley.Hillard@UHhospitals.org).